2238 Mookerjee, Bijoyesh P. - Thomas Jefferson University - Thomas Jefferson University
Dr. Mookerjee

Bijoyesh P. Mookerjee, MD

Contact Dr. Mookerjee

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
  2. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A randomized Phase II study
  3. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)
  4. Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
  5. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  6. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  7. Adenovirus DNA polymerase is recognized by human CD8+ T cells
  8. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  9. T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions
  10. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  11. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
  12. Cytoprotection in acute myelogenous leukemia (AML) therapy
  13. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  14. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
  15. Overcoming drug resistance: Targeting more than one site
  16. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
  17. Autologous stem cell transplantation (ASCT) followed by consolidation chemotherapy for multiple myeloma (MM)
  18. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia- inducible factor 1α
  19. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
  20. p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300
0